Mariner
RXRX icon

Mariner’s Recursion Pharmaceuticals RXRX Stock Holding History

Mariner’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-93,581
Closed -$457K – 3771
2025
Q3 		$457K Buy
93,581
+5,297
+6% +$27.8K ﹤0.01% 2507
2025
Q2 		$447K Sell
88,284
-19,457
-18% -$95.6K ﹤0.01% 2421
2025
Q1 		$570K Sell
107,741
-3,322
-3% -$24.2K ﹤0.01% 2104
2024
Q4 		$751K Buy
111,063
+27,499
+33% +$185K ﹤0.01% 1853
2024
Q3 		$551K Buy
83,564
+2,469
+3% +$17.7K ﹤0.01% 2049
2024
Q2 		$608K Buy
81,095
+1,192
+1% +$10.4K ﹤0.01% 1902
2024
Q1 		$797K Buy
79,903
+52
+0.1% +$579 ﹤0.01% 1673
2023
Q4 		$787K Sell
79,851
-604
-0.8% -$4.31K ﹤0.01% 1609
2023
Q3 		$615K Sell
80,455
-50,575
-39% -$505K ﹤0.01% 1634
2023
Q2 		$979K Sell
131,030
-61,126
-32% -$428K ﹤0.01% 1326
2023
Q1 		$1.28M Sell
192,156
-6,569
-3% -$52.1K ﹤0.01% 1151
2022
Q4 		$1.53M Sell
198,725
-763
-0.4% -$7.48K ﹤0.01% 1033
2022
Q3 		$2.12M Buy
199,488
+24,951
+14% +$253K 0.01% 749
2022
Q2 		$1.42M Buy
174,537
+146,418
+521% +$980K 0.01% 802
2022
Q1 		$201K Buy
+28,119
New +$299K ﹤0.01% 1378

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Mariner's RXRX Position: Q4 2025 in Review

Mariner sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 93,581 shares — an estimated $457K sold.

Mariner first reported a position in RXRX in Q1 2022 and held it in 15 quarters. The position peaked at $2.12M in Q3 2022. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Mariner reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 93,581 Recursion Pharmaceuticals shares in Q4 2025, an estimated $457K.
  • Mariner first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 15 quarters.
  • Mariner's Recursion Pharmaceuticals position peaked at $2.12M in Q3 2022.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.